CONSENSUS STATEMENT

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007

D E Furst¹, F C Breedveld², J R Kalden³, J S Smolen⁴, G R Burmester⁵, J Sieper⁶, P Emery⁷, E C Keystone⁸, M H Schiff⁹, P Mease¹⁰, P L C M van Riel¹¹, R Fleischmann¹², M H Weisman¹³, M E Weinblatt¹⁴

¹ David Geffen School of Medicine, Los Angeles, California, USA
² Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands
³ Department of Internal Medicine III, Institut for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
⁴ Institute of Rheumatology, Clinic for Internal Medicine III, Vienna General Hospital, Vienna, Austria
⁵ Department of Rheumatology, and Clinical Immunology, Charité Hospital, Berlin, Germany
⁶ University Clinic Benjamin Franklin, Germany
⁷ Leeds University, Department of Rheumatology, Leeds General Infirmary, Leeds, UK
⁸ Department of Rheumatology, Mount Sinai Hospitial, Toronto, Canada
⁹ Denver Arthritis Clinic, Denver, Colorado, USA
¹⁰ Seattle Rhumatology Associates, Seattle, Washington 98104, USA
¹¹ University Nijmegen Medical Centre, Nijmegen, The Netherlands
¹² University of Texas Southwestern Medical Center, Dallas, Texas USA
¹³ Cedar Sinai Hospital, Los Angeles, California, USA
¹⁴ Brigham and Women's Hospital, Boston, Massachusetts, USA

Correspondence to:
D E Furst, David Geffen School of Medicine, UCLA – RM 32-59, 1000 Veteran Avenue, Los Angeles, CA 90025, USA; defurst@mednet.ucla.edu

Abbreviations: abs, abstract; ACR, American College of Rheumatology; ANA, antinuclear antibody, AS, ankylosing spondylitis; ASCVD, atherosclerotic cardiovascular disease; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; CDAI, Clinical Disease Activity Index; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; DAS, Disease Activity Score; DMARD, disease-modifying antirheumatic drug; FDA, Food and Drug Administration; HAQ-DI, Health Assessment Questionnaire disability index; MTX, methotrexate; PPD, purified protein derivative; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SDAI, Simple Disease Activity Index; TB, tuberculosis; VAS, visual analogue scale

The first 150 words of the full text of this article appear below.

As in previous years, the consensus group to consider the use of biological agents was constituted by rheumatologists from the universities of Erlangen, Leiden and Vienna in Europe in cooperation with other universities in the USA, Canada and Europe. Pharmaceutical industry support was obtained from a number of companies, but these companies had no part in the decisions regarding the specific programme or about the academic participants at this conference. These sponsors participated in the initial small breakout groups with emphasis on supplying factual information. The companies, on the other hand, had no part in the larger, final consensus group or in the final consensus statement.

The perspective of this consensus is from the treating physician’s point of view.

The 160 rheumatologists and bioscientists who attended the consensus conference were chosen from a worldwide group of physicians and other scientists from 21 countries, with expertise in the use of biological . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Saw, V. P. J., Dart, R. J. C., Galatowicz, G., Daniels, J. T., Dart, J. K. G., Calder, V. L. (2009). Tumor Necrosis Factor-{alpha} in Ocular Mucous Membrane Pemphigoid and Its Effect on Conjunctival Fibroblasts. IOVS 50: 5310-5317 [Abstract] [Full Text]  
• SPADARO, A., SCRIVO, R., SPINELLI, F. R., VALESINI, G. (2009). Monitoring Biological Therapies in Psoriatic Arthritis. The Journal of Rheumatology Supplement 83: 69-70 [Abstract] [Full Text]  
• Frank, K. M., Hogarth, D. K., Miller, J. L., Mandal, S., Mease, P. J., Samulski, R. J., Weisgerber, G. A., Hart, J. (2009). Investigation of the Cause of Death in a Gene-Therapy Trial. NEJM 361: 161-169 [Abstract] [Full Text]  
• Mueller, M. C., Fleischmann, E., Grunke, M., Schewe, S., Bogner, J. R., Loscher, T. (2009). Relapsing Cutaneous Leishmaniasis in a Patient with Ankylosing Spondylitis Treated with Infliximab. Am J Trop Med Hyg 81: 52-54 [Abstract] [Full Text]  
• Fleischmann, R, Vencovsky, J, van Vollenhoven, R F, Borenstein, D, Box, J, Coteur, G, Goel, N, Brezinschek, H-P, Innes, A, Strand, V (2009). Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 68: 805-811 [Abstract] [Full Text]  
• Geens, E., Geusens, P., Vanhoof, J., Berghs, H., Praet, J., Esselens, G., Lens, S., Dufour, J.-P., Vandenberghe, M., Van Mullem, X., Westhovens, R., Verschueren, P. (2009). Belgian rheumatologists' perception on eligibility of RA patients for anti-TNF treatment matches more closely Dutch rather than Belgian reimbursement criteria. Rheumatology (Oxford) 48: 546-550 [Abstract] [Full Text]  
• Bruce, S. P. (2009). Recent Developments in the Treatment of Rheumatoid Arthritis. Journal of Pharmacy Practice 22: 65-74 [Abstract]  
• Eroschenko, K., Cleveland, K. W., Gunter, K. (2009). Psoriatic Arthritis: A Review. Journal of Pharmacy Practice 22: 86-103 [Abstract]  
• Borte, S., Liebert, U. G., Borte, M., Sack, U. (2009). Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatology (Oxford) 48: 144-148 [Abstract] [Full Text]  
• Furst, D E, Keystone, E C, Kirkham, B, Fleischmann, R, Mease, P, Breedveld, F C, Smolen, J S, Kalden, J R, Burmester, G R, Braun, J, Emery, P, Winthrop, K, Bresnihan, B, De Benedetti, F, Dorner, T, Gibofsky, A, Schiff, M H, Sieper, J, Singer, N, Van Riel, P L C M, Weinblatt, M E, Weisman, M H (2008). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 67: iii2-iii25 [Full Text]  
• Smolen, J. S, Weinblatt, M. E (2008). When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step?. Ann Rheum Dis 67: 1497-1498 [Full Text]  
• Fautrel, B., Flipo, R. M., Saraux, A. (2008). Eligibility of rheumatoid arthritis patients for anti-TNF-{alpha} therapy according to the 2005 recommendations of the French and British Societies for Rheumatology. Rheumatology (Oxford) 47: 1698-1703 [Abstract] [Full Text]  
• Pocock, J. M., Vasconcelos, J. C., Ostor, A. J. K. (2008). Assessment of anti-TNF-{alpha} efficacy in rheumatoid arthritis: is 3 months sufficient?. Rheumatology (Oxford) 47: 1073-1076 [Abstract] [Full Text]  

eLetters:

Read all eLetters

Guidelines for the use of biologics

Andrew JK Östör, et al.

Ann Rheum Dis Online, 8 Feb 2008 [Full text]